Kabazitaksel Fresenius Kabi

Cabazitaxel, the active ingredient in Kabazitaksel Fresenius Kabi, is a taxane presented as an injectable solution for intravenous use. It is indicated for the treatment of metastatic castration‑resistant prostate cancer in patients who have progressed after prior docetaxel therapy.

GNH USA supplies Kabazitaksel Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kabazitaksel Fresenius Kabi is a taxane chemotherapy used in the management of advanced prostate cancer.

- Metastatic castration‑resistant prostate cancer: improves overall survival and disease control in patients previously treated with docetaxel.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss on scalp and body. - Nausea: upset stomach often accompanied by vomiting.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe hypersensitivity: anaphylactic reactions such as rash, swelling, or breathing difficulty. - Pulmonary toxicity: inflammation of lung tissue causing cough and shortness of breath.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events. - Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess hepatic function: check liver enzymes because cabazitaxel is metabolized hepatically. - Evaluate cardiac status: consider baseline ECG in patients with cardiac disease. - Avoid in severe infections: postpone treatment if active infection is present. - Use effective contraception: cabazitaxel may cause fetal harm. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase cabazitaxel exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Other myelosuppressive agents: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): may require dose adjustment. - Anticoagulants (e.g., warfarin): increased bleeding risk, monitor coagulation parameters.